Recent advances in the pharmacology of rilmenidine.

[1]  M. Dontenwill,et al.  Rilmenidine selectivity for imidazoline receptors in human brain. , 1989, European journal of pharmacology.

[2]  P. Valet,et al.  Rilmenidine (S 3341) and the sympathoadrenal system: adrenoreceptors, plasma and adrenal catecholamines in dogs. , 1988, Journal of autonomic pharmacology.

[3]  M. Dontenwill,et al.  Evidence for the existence of a homogeneous population of imidazoline receptors in the human brainstem. , 1988, European journal of pharmacology.

[4]  P. A. Zwieten.  Pharmacology of the alpha2-adrenoceptor agonist rilmenidine , 1988 .

[5]  F. Lhoste,et al.  Cardiovascular and central nervous system effects of rilmenidine (S 3341) in rats. , 1988, The American journal of cardiology.

[6]  W. Louis,et al.  Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine (S 3341) on cardiovascular and behavioral parameters of spontaneously hypertensive rats. , 1988, The American journal of cardiology.

[7]  S. File,et al.  Comparison of the effects of clonidine, rilmenidine, and guanfacine in the holeboard and elevated plus‐maze , 1988 .

[8]  R. Podevin,et al.  Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney. , 1987, Biochemical and biophysical research communications.

[9]  B. Jarrott,et al.  Rapid Eye Movement Sleep and the Associated Cardiovascular Changes During and After Continuous 10‐Day Infusion of Clonidine in Normotensive Rats: Comparison with Lofexidine and S3341 , 1987, Journal of cardiovascular pharmacology.

[10]  A. Herman,et al.  Effect of the amino-oxazoline derivative S-3341 on pre- and postjunctional alpha-adrenoceptors in isolated blood vessels. , 1986, Archives internationales de pharmacodynamie et de therapie.

[11]  D. Atlas,et al.  An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. , 1986, European journal of pharmacology.

[12]  D. Reis,et al.  An endogenous clonidine-like substance binds preferentially to imidazole binding sites in the ventrolateral medulla labelled by 3H-para-aminoclonidine , 1986 .

[13]  P. Timmermans,et al.  Central and peripheral effects of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models. , 1986, Archives internationales de pharmacodynamie et de therapie.

[14]  J. Scuvée-Moreau,et al.  Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S 3341), an alpha-2 adrenoceptor agonist. , 1985, Journal de pharmacologie.

[15]  Y. Burstein,et al.  Isolation and partial purification of a clonidine-displacing endogenous brain substance. , 1984, European journal of biochemistry.

[16]  J. Schwartz,et al.  Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. , 1984, The Journal of pharmacology and experimental therapeutics.

[17]  A. Roach,et al.  Sleeping times evoked by alpha adrenoceptor agonists in two-day-old chicks: an experimental model to evaluate full and partial agonists at central alpha-2 adrenoceptors. , 1983, The Journal of pharmacology and experimental therapeutics.

[18]  M. Brown,et al.  IS ADRENALINE THE CAUSE OF ESSENTIAL HYPERTENSION? , 1981, The Lancet.

[19]  H. Y. Kwa,et al.  Characterization of alpha-adrenoceptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine. , 1981, European journal of pharmacology.

[20]  B. Glass.  Biochemistry of the Developing Nervous System , 1956 .